Cure8 trial brief
People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its abundance links to clinical outcomes, which could inform future prevention or treatment research.
Patients with IBD on anti‑TNFα therapies (and those with inflammatory skin lesions), dermatologists, gastroenterologists, microbiome researchers, and clinicians running IBD biologic clinics.
This is a planned, not-yet-recruiting observational study registered on ClinicalTrials.gov and led by a French university hospital. Its primary measurements are the percent of sequencing reads mapping to S. aureus in lesion and control swabs at baseline and month 6, plus correlation with a Physician’s Global Assessment of lesion severity.
The protocol focuses on skin microbiota sequencing (microbiome testing) and standard cultures from swabs, with longitudinal clinical follow-up to see whether changes in S. aureus abundance accompany improvement or worsening of lesions. No results are reported in the record.
If you follow anti‑TNFα therapy and have inflammatory skin lesions, this study aims to better characterize the role of S. aureus carriage in those lesions but does not itself test a treatment change.
This is a registered, observational trial that is not yet recruiting and does not report results. The record outlines planned sampling, sequencing, and clinical assessments but does not provide data—interpretation should wait for study completion and peer review.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
